EL7.AI
StocksMedium•6 November 2026•
4 min read

Alpmed Files for U.S. and EU Clearance of IRE System

Key Facts

1Alpmed submitted a 510(k) notification to the FDA and an application for European conformity assessment for the IRE system on November 5, 2026.
2The companies are targeting potential FDA clearance and CE marking in 2027, subject to the outcome of the reviews.
3Baird Medical received a Nasdaq notice of noncompliance with the minimum bid price requirement on November 4, 2026.
4Nasdaq’s compliance period ends on May 3, 2027, and requires a closing price of $1.00 or more for at least 10 consecutive business days.

Baird Medical said on November 5, 2026, that its partner Alpmed had submitted a 510(k) notification to the U.S. Food and Drug Administration and an application for European conformity assessment for its non-thermal irreversible electroporation system, opening a regulatory review path in two major markets. The companies are targeting FDA clearance and CE marking in 2027, subject to the outcome of the reviews, according to the company’s statement. The notification and application begin regulatory assessment but do not mean approvals have been granted. The filing statement did not establish that the step explained Baird Medical’s after-hours share movement or the decline percentage cited in the draft. A day earlier, the company had said it was unaware of any material developments or undisclosed reasons to explain its recent share-price decline.

A 510(k) submission means the system’s filing has been submitted to the U.S. agency for consideration under the regulatory pathway, while the European filing seeks the conformity assessment required for CE marking. Baird Medical did not say in its statement that either review had resulted in a final decision. The 2027 target remains contingent on the outcome of both reviews, the company said, and is not a confirmed date for clearance or marking. Baird Medical manages the system’s global regulatory engagement, making it the party leading regulatory communications in the partnership. The company also retains the system’s global commercial rights, according to its statement.

The IRE system is designed to ablate soft tissue and may be suitable for treating multiple types of tumors, according to the company’s description. Baird Medical says the technology is non-thermal and uses high-voltage electrical pulses to disrupt cell membranes and induce cell death. The company says the approach may offer an option in cases near sensitive anatomical structures, where thermal ablation may not be the optimal solution. However, this potential use remains subject to regulatory assessment, and the statement did not announce approval of the cited therapeutic uses. Chief Executive Hai Mei Wu said adding the technology to the portfolio could expand the company’s treatment opportunities if the system receives clearance.

Wu said: "If cleared, adding IRE to our portfolio could offer additional opportunities to address therapeutic indications for which thermal ablation may not be the optimal solution." The statement ties potential commercial expansion to regulatory clearance and does not present it as an outcome already achieved. The step is part of Baird Medical’s collaboration with Alpmed; the company said the two submissions were completed less than three months after the collaboration agreement was signed. That timeline reflects the speed of completing the filings since the partnership began, according to the company, while regulatory reviews remain the next stage. The statement gave no details on interim timelines for the reviews before the 2027 target.

Two statements from Baird Medical on November 4, 2026, about its share price preceded the regulatory announcement. The company said then that it was unaware of any material developments or undisclosed reasons to explain the recent decline in its share price. On the same day, it announced that it had received a notice from Nasdaq stating that it did not comply with the minimum bid price requirement. It said the notice did not result in immediate delisting and that trading in the shares would continue. These disclosures place the new regulatory filings in the context of company news over the preceding two days, without establishing that Alpmed’s applications caused the share movements.

Nasdaq granted the company a 180-day compliance period ending on May 3, 2027, Baird Medical said. Regaining compliance requires the bid price to close at $1.00 per share or higher for at least 10 consecutive business days. The company said the notice does not result in immediate delisting, but the price requirement remains in effect during the compliance period. Separately, the companies are targeting FDA clearance and CE marking in 2027, subject to the outcome of the regulatory reviews. The company’s statement gives no more specific date for either regulatory decision and does not link them to Nasdaq’s deadline.